Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as azithromycin immediate release (Zithromax)
azithromycin immediate release · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| azithromycin immediate release (Zithromax) | DRUG | azithromycin IR 500 mg tablet by mouth for 1 dose |
| placebo | OTHER | placebo |
| azithromycin SR | DRUG | 2.0 g by mouth in the form of liquid for 1 dose |
Inclusion Criteria: Inclusion criteria were hospitalized subjects diagnosed with lung cancer that had consented to surgery requiring lung resection who had a life expectancy of \>6 months. Exclusion Criteria: Key exclusion criteria were antibiotic prophylaxis prior to surgery, diffuse, non-infect...
Azithromycin immediate release is a small molecule form of azithromycin, the macrolide antibiotic also marketed as Zithromax. Pfizer, Inc. (ticker PFE) is the developer. The immediate release designation refers to the standard tablet formulation that releases the drug promptly after dosing, as opposed to a sustained release version.
Pfizer, Inc., which trades under the ticker PFE, is the developer of azithromycin immediate release. The drug is also known as Zithromax. Pfizer conducted the clinical work described for this formulation, including a pharmacokinetic study in cancer patients requiring lung surgery.
Azithromycin immediate release has been studied in Phase 2 clinical development. The recorded trial is completed, and no active trials are listed. The program has one completed Phase 2 study with 66 enrolled participants. It is an investigational use in this pharmacokinetic setting rather than a newly approved product.
Azithromycin immediate release was evaluated in one completed Phase 2 trial, NCT00644176. The study was a randomized, open label, controlled pharmacokinetic trial comparing a single 2 gram dose of azithromycin sustained release with a commercial 500 mg azithromycin tablet in cancer patients requiring lung surgery. It enrolled 66 participants in Italy.
Yes, azithromycin immediate release is also known as azithromycin immediate release (Zithromax). Zithromax is the brand name associated with this azithromycin formulation developed by Pfizer, Inc. (ticker PFE). The immediate release description distinguishes the standard tablet from the sustained release 2 gram version tested in the same pharmacokinetic study.
Trial NCT00644176 examined the pharmacokinetics of azithromycin in cancer patients who required lung surgery. It was a randomized, open label, controlled Phase 2 study comparing a single 2 gram dose of azithromycin sustained release with a commercial 500 mg azithromycin tablet. The trial enrolled 66 adults in Italy and is completed.